Mobile

A randomised, double blind, placebo-controlled, multiple dose, dose-escalating, sequential dose group trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-...

Update Il y a 4 ans
Reference: EUCTR2008-001061-29

A randomised, double blind, placebo-controlled, multiple dose, dose-escalating, sequential dose group trial investigating safety, tolerability, pharmacokinetics and pharmacodynamics of pegylated long-acting human growth hormone (NNC126-0083) in Growth Hormone deficient adults (AGHD)

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To determine safety and tolerability of ascending multiple subcutaneous (sc) doses of NNC126-0083 in AGHD male and female subjects compared to placebo.

Inclusion criteria

  • Growth hormone deficiency

Links